GB0907601D0 - Novel methods - Google Patents

Novel methods

Info

Publication number
GB0907601D0
GB0907601D0 GBGB0907601.9A GB0907601A GB0907601D0 GB 0907601 D0 GB0907601 D0 GB 0907601D0 GB 0907601 A GB0907601 A GB 0907601A GB 0907601 D0 GB0907601 D0 GB 0907601D0
Authority
GB
United Kingdom
Prior art keywords
novel methods
novel
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0907601.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Pharma Callanish Ltd
Original Assignee
Equateq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equateq Ltd filed Critical Equateq Ltd
Priority to GBGB0907601.9A priority Critical patent/GB0907601D0/en
Publication of GB0907601D0 publication Critical patent/GB0907601D0/en
Priority to JP2012507808A priority patent/JP5608220B2/ja
Priority to EP10717725A priority patent/EP2424519A1/en
Priority to PCT/GB2010/000817 priority patent/WO2010125330A1/en
Priority to US13/318,420 priority patent/US20120122982A1/en
Priority to NZ596674A priority patent/NZ596674A/xx
Priority to SG2011080280A priority patent/SG175848A1/en
Priority to CN201080023442.8A priority patent/CN102448453B/zh
Priority to CA2762009A priority patent/CA2762009C/en
Priority to KR1020117028669A priority patent/KR101664518B1/ko
Priority to MX2011011615A priority patent/MX2011011615A/es
Priority to AU2010243368A priority patent/AU2010243368C1/en
Priority to BRPI1009922A priority patent/BRPI1009922A2/pt
Priority to ZA2011/08571A priority patent/ZA201108571B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0907601.9A 2009-05-01 2009-05-01 Novel methods Ceased GB0907601D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
BRPI1009922A BRPI1009922A2 (pt) 2009-05-01 2010-04-22 uso de um composto derivado de ácido graxo poli-insaturado,composição farmacêutica,e, método para tratar ou provenir dano nem nervo.
SG2011080280A SG175848A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage
CA2762009A CA2762009C (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage
US13/318,420 US20120122982A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage
NZ596674A NZ596674A (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage
JP2012507808A JP5608220B2 (ja) 2009-05-01 2010-04-22 神経損傷の治療を目的としたｐｕｆａの使用
CN201080023442.8A CN102448453B (zh) 2009-05-01 2010-04-22 多不饱和脂肪酸在治疗神经损伤中的用途
EP10717725A EP2424519A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage
KR1020117028669A KR101664518B1 (ko) 2009-05-01 2010-04-22 신경손상을 치료하기 위한 다중불포화 지방산(ｐｕｆａｓ)의 용도
MX2011011615A MX2011011615A (es) 2009-05-01 2010-04-22 Uso de acidos grasos poliinsaturados (pufas) para tratar daño del nervio.
AU2010243368A AU2010243368C1 (en) 2009-05-01 2010-04-22 Use of PUFAs to treat nerve damage
ZA2011/08571A ZA201108571B (en) 2009-05-01 2011-11-22 Use of pufas to treat nerve damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods

Publications (1)

Publication Number Publication Date
GB0907601D0 true GB0907601D0 (en) 2009-06-10

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0907601.9A Ceased GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods

Country Status (14)

Country Link
US (1) US20120122982A1 (enExample)
EP (1) EP2424519A1 (enExample)
JP (1) JP5608220B2 (enExample)
KR (1) KR101664518B1 (enExample)
CN (1) CN102448453B (enExample)
AU (1) AU2010243368C1 (enExample)
BR (1) BRPI1009922A2 (enExample)
CA (1) CA2762009C (enExample)
GB (1) GB0907601D0 (enExample)
MX (1) MX2011011615A (enExample)
NZ (1) NZ596674A (enExample)
SG (1) SG175848A1 (enExample)
WO (1) WO2010125330A1 (enExample)
ZA (1) ZA201108571B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2015071766A1 (en) * 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE10940T1 (de) * 1981-05-12 1985-01-15 Imperial Chemical Industries Plc Pyrrolderivate.
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
KR910005856B1 (ko) * 1987-09-16 1991-08-05 다이호야꾸힝고오교가부시끼가이샤 티에노피리미딘 유도체
DE69433713T2 (de) * 1993-06-09 2005-04-07 Martek Biosciences Corp. Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
CZ20023562A3 (cs) * 2000-04-28 2003-03-12 Sankyo Company, Limited PPAR gama modulátory
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
CA2480429C (en) * 2002-03-25 2008-09-16 Biosynergen, Inc. Novel therapeutical use of agonist ligands specific to g2a receptor
JP4972745B2 (ja) * 2005-06-22 2012-07-11 国立大学法人群馬大学 Ｇタンパク質共役型受容体ｇ２ａの作動薬、及びｇ２ａ活性調節薬のスクリーニング方法
JP5366211B2 (ja) * 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物

Also Published As

Publication number Publication date
NZ596674A (en) 2013-09-27
EP2424519A1 (en) 2012-03-07
AU2010243368B2 (en) 2013-10-24
AU2010243368C1 (en) 2014-04-03
KR101664518B1 (ko) 2016-10-11
WO2010125330A1 (en) 2010-11-04
KR20120023729A (ko) 2012-03-13
AU2010243368A1 (en) 2011-12-15
SG175848A1 (en) 2011-12-29
CA2762009C (en) 2016-11-22
CN102448453A (zh) 2012-05-09
BRPI1009922A2 (pt) 2016-03-15
US20120122982A1 (en) 2012-05-17
MX2011011615A (es) 2012-01-27
CN102448453B (zh) 2016-07-06
JP2012525362A (ja) 2012-10-22
ZA201108571B (en) 2013-01-30
CA2762009A1 (en) 2010-11-04
JP5608220B2 (ja) 2014-10-15

Similar Documents

Publication Publication Date Title
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
GB0907413D0 (en) Novel methods
DK2442650T4 (en) Sublingualt apomorfin
EP2462514A4 (en) GREEN BOOKS
GB0909645D0 (en) Methods
EP2515891A4 (en) 3-keto-N-propargyl-1-aminoindan
ZA201109437B (en) Novel azabicyclohexanes
GB0907350D0 (en) Methods
IL214232A0 (en) Novel tricyanoborates
EP2519921A4 (en) CALL TRACING
GB0901001D0 (en) Methods
DK2464943T3 (en) Systemintegration
GB0912685D0 (en) Methods
GB0900555D0 (en) New methods
GB0907601D0 (en) Novel methods
GB0912159D0 (en) Methods
GB0903026D0 (en) Novel method
GB0900568D0 (en) Poymerisation
GB0900319D0 (en) Hydrocharger
EP2510125A4 (en) HYPER PRIMER
AU4926P (en) Bonscalib Scaevola aemula
AU4925P (en) Bonscawi Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
AU4924P (en) Bonscablue Scaevola aemula

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)